A carrier-assisted ChIP-seq method for estrogen receptor-chromatin interactions from breast cancer core needle biopsy samples
暂无分享,去创建一个
E. Rutgers | J. Carroll | W. Zwart | S. Linn | J. Wesseling | R. Koornstra | Emiel Rutgers | Jelle Wesseling | Wilbert Zwart | Jason S Carroll | Rutger Koornstra | Sabine Linn
[1] V. Theodorou,et al. Oestrogen receptor–co‐factor–chromatin specificity in the transcriptional regulation of breast cancer , 2011, The EMBO journal.
[2] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[3] A. Floore,et al. Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer. , 2004, Cancer cell.
[4] Tao Liu,et al. CEAS: cis-regulatory element annotation system , 2009, Bioinform..
[5] Mazhar Adli,et al. Genome-wide chromatin maps derived from limited numbers of hematopoietic progenitors , 2010, Nature Methods.
[6] Clifford A. Meyer,et al. Model-based Analysis of ChIP-Seq (MACS) , 2008, Genome Biology.
[7] Jérôme Eeckhoute,et al. Growth factor stimulation induces a distinct ER(alpha) cistrome underlying breast cancer endocrine resistance. , 2010, Genes & development.
[8] J. Baselga,et al. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. , 2001, Cancer research.
[9] Rory Stark. Differential Oestrogen Receptor Binding is Associated with Clinical Outcome in Breast Cancer , 2012, RECOMB.
[10] Z. Szallasi,et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients , 2010, Breast Cancer Research and Treatment.
[11] C. Mathers,et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.
[12] J. Savulescu,et al. No consent should be needed for using leftover body material for scientific purposes , 2002, BMJ : British Medical Journal.
[13] Mazhar Adli,et al. Whole-genome chromatin profiling from limited numbers of cells using nano-ChIP-seq , 2011, Nature Protocols.
[14] Li Wang,et al. Single-tube linear DNA amplification (LinDA) for robust ChIP-seq , 2011, Nature Methods.
[15] Michael D. Wilson,et al. ChIP-seq: using high-throughput sequencing to discover protein-DNA interactions. , 2009, Methods.
[16] K. Jirström,et al. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients. , 2006, Journal of the National Cancer Institute.
[17] E. Liu,et al. An Oestrogen Receptor α-bound Human Chromatin Interactome , 2009, Nature.
[18] Jun Song,et al. CEAS: cis-regulatory element annotation system , 2006, Nucleic Acids Res..
[19] S. Hilsenbeck,et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. , 2003, Journal of the National Cancer Institute.
[20] R. Schiff,et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. , 2004, Journal of the National Cancer Institute.
[21] Clifford A. Meyer,et al. Genome-wide analysis of estrogen receptor binding sites , 2006, Nature Genetics.
[22] I. Ellis,et al. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer , 2011, Nature.
[23] B. Turner,et al. Epigenetic characterization of the early embryo with a chromatin immunoprecipitation protocol applicable to small cell populations , 2006, Nature Genetics.
[24] M. Dillon,et al. Coassociation of Estrogen Receptor and p160 Proteins Predicts Resistance to Endocrine Treatment; SRC-1 is an Independent Predictor of Breast Cancer Recurrence , 2009, Clinical Cancer Research.
[25] P. V. van Diest. No consent should be needed for using leftover body material for scientific purposes. For. , 2002, BMJ.
[26] Clifford A. Meyer,et al. Nucleosome Dynamics Define Transcriptional Enhancers , 2010, Nature Genetics.